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Abstract
Background: Globally, osteoarthritis (OA) is the third condition associated with disability. There is still poor
treatment in OA but science holds the key to finding better treatments and a cure. It is essential to learn what’s
important to patients from them to implement the most effective OA management. The OA Patients Task Force,
conducted the Global OA Patient Perception Survey (GOAPPS)-the first global survey made by patients to analize
the quality of life (QoL) & patient perceptions of care. The goal was to collect data on OA patients’ perception of
OA to understand patients’ needs and expectations to improve OA management.
Methods: Observational, cross-sectional study by online survey data collection from six countries, translated into
three languages. The questionnaire was comprised of 3 sections: patient demographics and clinical symptomology
characteristics; relationship with physicians: perception of attention, treatment, and information provided; and OA
impact on daily activity and QoL. The results of the survey were evaluated using the Limited Data Set. The survey
results were analyzed using descriptive statistics to characterize the patients’ answers. Additionally, Cronbach’s alpha
was calculated to determine internal consistency validity.
Results: A total of 1512 surveys were completed in 6 countries. 84.2% of respondents reported pain/tenderness
and 91.1% experienced limitations to physical activities. 42.3% of patients were not satisfied with their current OA
treatment. 86% had comorbidities, especially hypertension, and obesity. 51.3 and 78% would like access to
additional drug or additional non-drug/non-surgical treatments respectively. 48.2% of patients perceived their QoL
to be affected by OA. The Cronbach’s alpha was 0.61.
Conclusions: OA has a significant impact on patients’ daily activities and their desire to play an active role in
managing this disease. Patients are seeking additional treatments, especially no pharmacological/no surgical
treatments stressing the need for investing in clinical research, implementing OA preventive measures, and
managing interventions to improve the healthcare value chain in OA.
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Background
Globally, osteoarthritis (OA) is the most common mus-
culoskeletal disorder and it is associated with pain, dis-
ability, and quality-adjusted life-year losses [1–4]. From
1990 to 2013, the trend of Years Lived with Disabilities
(YLD) in OA increased 75%, being OA the third most
rapidly rising condition after diabetes and dementia [1].
Worldwide, around 300 million people suffer from OA.
Of these, more than 40 million adults live in Europe,
and over 30 million in the United States of America
(USA). In Latin America, the numbers of adults with
OA are only partially available [1, 5, 6]. Adults afflicted
with OA display different degrees of disability, ranging
from mild and intermittent pain, with minimal difficulty
in performing daily activities, to chronic pain with pro-
gressive structural damage and loss of function. Greater
disability is often associated with a decrease in mental
health and an increase in mortality when a person can
no longer walk or live independently [1].
Currently, there is no cure for OA. However, there is
increasing interest in developing OA interventions that
improve physical health and quality of life (QoL) while
reducing opioid or NSAID abuse and associated comor-
bidities [7–13]. To accomplish this, a consensus about
the outcomes that are relevant to OA patients, comorbid
populations, and other key stakeholders in OA requires
listening to patients’ opinions and experiences. Learning
what is important to patients from the patients them-
selves is essential to create a core outcome set to bridge
the gap between the patients’ needs and the current OA
management paradigms.
Integrated people-centered health services, as defined
by the World Health Organization, implies putting the
comprehensive needs of people and communities, not
only the conditions as such, at the center of health sys-
tems, and empowering people to have a more active role
in their health [14]. To support OA patients, the Osteo-
arthritis Foundation International (OAFI) (Barcelona,
Spain) and the Arthritis Foundation (Atlanta, USA) with
participation from important organizations fighting
against rheumatic disease worldwide such as the Pana-
merica League against Rheumatism (PANLAR) created
the OA Patients Task Force. This task force is a global
alliance working in the fight against OA and represent-
ing about 150 million patients.
In 2018, the OA Patients Task Force developed the
Global OA Patient Perception Survey (GOAPPS). This
was the first international survey developed by patients'
organizations to investigate OA patients’ perceptions of
QoL across many languages and nations/cultures using
the same questionnaire. This was a pilot study aims to
collect information on OA patients’ perceptions regard-
ing the impact of the disease in their lives to help all
stakeholders involved in OA healthcare and
management to better understand patients’ perceptions,
to address patient needs more effectively in terms of pre-
vention, research, and management [15].
Methods
This observational, cross-sectional study collected data
through an online survey in six countries where member
organizations of the OA Patients Task Force were based:
Colombia, Spain, Italy, Mexico, the USA, and Venezuela.
It was a hypothesis generating research aim to collect a
set of data to decipher the relationship and patterns
existing between different aspects of patient’s percep-
tions of QoL.
Patients were required to meet the following inclusion
criteria to be eligible for this study: (i) being residents of
one of the participant countries, (ii) being older than 18
years, and (iii) reporting to have been diagnosed with
OA by their physician.
Questionnaire development
The questionnaire was developed by researchers collab-
orating with the OA Patients Task Force and included
expert patients, rheumatologists, clinical pharmacolo-
gists, epidemiologists and, patient advocates.
The first version of the questionnaire was written in
English, then was translated into Spanish and Italian
using a specific protocol of forward translation, back
translation, and resolution. The translation process was
supervised by the Survey Coordinator designated in each
region.
During forward translation, a health professional famil-
iar with relevant terminology, fluent in English but whose
mother tongue was the primary language of the target
culture, translated the survey from English to the local
language. The focus was on conceptual rather than literal
translation and the use of natural and acceptable lan-
guage for the broadest audience. During back translation,
a different translator who was a native English speaker
translated the survey from the local language to English.
The forward translator, back translator, and Survey
Coordinator met to resolve any concerns or discrepan-
cies in the forward translated language. The Survey Co-
ordinator sent the translation documentation to
international Project Coordinators to ensure coordin-
ation of survey language across participating countries.
The final questionnaire was divided into 3 sections
with an acknowledgment statement that read: “By enter-
ing the survey, I indicate that I have read the informa-
tion provided and agree to participate.” The first section
of the survey included patient demographics and clinical
characteristics questions. The second section of the sur-
vey focused on patient relationships with physicians and
explored the personal perception of attention, treatment,
and information received. In the last section of the
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survey, patients were asked to evaluate their QoL. Fi-
nally, two questions were added to explore the patients’
interest in the survey results and their willingness to par-
ticipate in a future survey on OA.
The OAFI Patients Committee, composed of 15 volun-
teers OA patients, evaluated the ethical aspects of the
final version of the questionnaire. The members of the
OAFI Patients Committee approved the questionnaire
compliant with patient use.
Cronbach’s alpha was used to measure the reliability
of the global questionnaire. The Cronbach’s alpha was
0.61. Cronbach’s alpha value of 0.60 is accepted by the
scientific community in the case of exploratory research
[16]. Newly developed instruments can be accepted with
an alpha value of 0.60 [17].
Survey execution
The engagement with patients occurred in two stages: 1)
a pilot test and 2) the online administration.
During the pilot test, the local Survey Coordinators
administrate the questionnaire to 10 volunteer patients
who met the inclusion criteria to evaluate the question-
naire burden, acceptability, and comprehensibility. As a
result, some questions were modified to avoid unfamiliar
terms or removed to shorten or avoid repetition (Add-
itional file 1).
The final survey was administered by the Arthritis
Foundation using the online secured Qualtrics platform
from June to November 2018, a survey software allowing
to conduce personalized surveys. The local Survey Co-
ordinator administrated the survey in each country
through collaboration with local organizations that pro-
moted access to the survey webpage using social media,
brochures, or other promotional materials.
The results of the survey were evaluated using the
Limited Data Set. The survey results were analyzed using
descriptive statistics to characterize the patients’ answers
using the IBM SPSS® software.
This survey was considered a pilot study.
Results
Demographic and clinical data
A total of 1683 patients entered the online survey. One
thousand five hundred twelve entries were considered
correctly completed. The final sample includes patients
from the USA, Spain, Colombia, Venezuela, Mexico,
Italy. The demographic data of patients surveyed are
shown in Table 1.
The survey results indicated the majority of patients
were diagnosed with knee OA (60.7%; 918 patients out of
1512). This was followed by hand OA (31.7%; 479 patients
out of 1512), spine OA (21.1%; 319 patients out of 1512),
and hip OA (8.3%; 126 patients out of 1512) (Fig. 1;
Additional file 2). Also, 435 (28.8%) of patients reported
having OA in other joints, mainly feet, shoulder, and ankle
(Additional file 3). The survey did not limit the number of
OA diagnoses so that patients could select all the OA lo-
cations that applied to their case.
Regarding comorbidities, 86% of respondents reported
being diagnosed with one or more comorbidities: 27.3%
reported having one comorbidity, while 24.6% and 16.5%
reported having two and three comorbidities respect-
ively. Arterial hypertension (45.6%) and obesity (36.7%)
were the most commons comorbidities reported. Gastro-
intestinal problems (26.1%) were the third most reported
comorbidity. Mental health problems, such as depression
and anxiety, had a high prevalence, as reported by 25.6
and 20.6% of respondents, respectively. Osteoporosis
was associated with OA in 22.6% of patients. Further-
more, 12.4% of OA patients suffered from diabetes.
(Fig. 2; Additional file 2).
Regarding OA symptoms, patients could select up
to three options. The combination of pain/tenderness,
stiffness, and gait/walk disturbance was the common-
est symptom reported that most significantly im-
pacted their daily life. 84.2% of patients declared
suffering for pain/tenderness, 48.9% for stiffness, and
37.7% of gait/walk disturbance. Also, loss of flexibility,
sleep disturbance, fatigue, and swelling were reported
as high prevalence symptoms in OA patients (Fig. 3;
Additional file 2).
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Patient-reported perceptions of patient-physician
relationships
When patients were asked about their relationships
with their doctors, about 7 in 10 patients (70.8%)
agreed or strongly agreed with the statement that
their doctors “understand” them when they describe
their OA symptoms (versus 13% who disagreed or
strongly disagree) and almost 6 in 10 patients (58.3%)
agreed or strongly agreed their doctor adequately ex-
plained their OA diagnosis and what it represented to
them (versus 22.1% disagreed or strongly disagreed).
While a little more than half of the patients (53.3%) stated
that they understood their OA treatment options and the
associated risks, almost one-quarter of patients (24.6%)
stated they did not understand their treatment options
and associated risks. Conversely, more than 4 in 10 pa-
tients (42.3%) were not satisfied with their current OA
treatment, while only about one-quarter of patients
(26.8%) stated they were satisfied with their current OA
treatment (Additional file 4).
Regarding the possibility of access to additional treat-
ment, the highest proportion of patients (78%) stated
they would like to have access to additional non-drug/
non-surgical treatments for their OA. This was followed
by a little over half of the patients (51.3%) who stated
they would like to have access to additional drug treat-
ment options for their OA and more than one-third of
patients (35%) who would like access to additional surgi-
cal treatment options. About 1 in 5 patients (18.9%)











Fig. 1 Joints with OA as reported by patients. Patients could select all the options that apply. Each column represents the localization(s) of OA as

























Fig. 2 Patients’ comorbidities as diagnosed by a medical doctor. Patients could select all the options that apply. Number of patients answering
this question = 1512. Number of answers = 3369
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and more than 1 in 3 patients (36%) were not interested
in additional surgical treatment options.
Patients’ perception of QoL
Regarding the limitations experienced due to OA,
91.1%% of the patients reported limitations in their
everyday life physical activities, followed by 49.1% of
patients reporting limitations to their work activities,
and 37% in social interactions. OA has emotional,
psychological, or mental health consequences in
almost one-third of respondents and limited their sex life
in 24.9% of patients. (Fig. 4; Additional files 2 and 5).
About half of the patients (51.7%) reported being satis-
fied with their QoL while the other half were either not
satisfied or not sure about their satisfaction with their
QoL (48.2%). When asked how their QoL would be if
their OA signs and symptoms were eliminated, 94.2% of
respondents said that their QoL would be good or very
good.
Finally, 74% of patients said that they would like to be
informed about the results of this study and 79% would
like to participate in future research on OA.
Discussion
OA is one of the most prevalent diseases affecting
people globally and is a leading cause of pain and dis-
ability among adults [18, 19]. Despite being such a wide-
spread and severe disease, it usually associates with the
false belief that it is a normal part of aging and that pa-
tients have to accept and live with it. This false myth, for
example, makes OA patients least likely to receive exer-
cise therapy and weight loss advice as recommended by
international clinical guidelines as a first-line treatment
for OA [20].
Empowering patients to have a more active role in
their health and engaging them in research are key as-
pects to ensure the effective implementation of interven-
tions aimed at improving QoL of patients and,





















Fig. 3 Clinical symptoms, which have the most significant impact on patients’ daily life as reported by patients. Patients can select up to three






Limitations to physical activities
Limitations on work activities
Limitations to social interactions
Emotional, psychological, or mental health issues
Limitations to sex life
Fig. 4 Limitations or issues experienced by patients due to OA. Number of patients answering this question = 1455. Number of answers = 3341
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Patients should be considered as another stakeholder
within the health system and patients’ organizations
should be considered as another healthcare agent,
present in real decision making, to make patient voice
be heard. It is necessary to know which outcomes are
relevant for patients to ensure their participation and
satisfaction.
The OA Patients Task Force, an international alliance
of patients’ organizations, has been working since 2016
on independent projects to make OA more visible and
to empower patients. The GOAPPS survey was a pilot
study designed to collect and analyze data on OA pa-
tients’ perceptions regarding their health conditions, OA
care, and to explore the impact of OA on daily function-
ing and QoL. The results aimed at providing a portrait
of patients’ perceptions of OA to provide a baseline to
take better quality performance in the future. As a pilot
study, it aimed to capture the necessary information to
carry out a large-scale survey able to compare cross-
cultural and cross-national data. Also, it was a proof of
concept study designed to prove the strength and cap-
acity of patients and their organizations to the scientific
community.
The results of this pilot study confirmed that OA can
be considered a gendered disease being more prevalent
among women [21–24]. Although, the fact that the ma-
jority of respondents were women can also be inter-
preted as women being more active and willing to
participate in these types of surveys. The prevalence of
OA increases with age in line with our results showing
that the age range with the highest prevalence of OA
was 65 to 74 years. However, almost a third of partici-
pants were 40 to 59 years indicating that OA also affects
younger groups of people like pre-menopausal women,
athletes, or injured people [25]. Finally, the majority of
the respondents were from the USA. This could be a
consequence of the different computer literacy existing
among the different countries that participated in the
survey. The data could also reflect the importance and
strength that patient organizations have in each country
which can associate with the structure of national health
systems.
The survey results revealed that OA patients are af-
fected by multiple comorbidities, especially arterial
hypertension and obesity. Notably, half of this popula-
tion suffers from depression and/or anxiety. The pres-
ence of comorbidities increases the frequency of physical
disability in patients with OA, and the impact on the
QoL of patients of the combination is greater than that
expected for OA alone or each isolated disease [18]. Co-
morbidities have been reported to be more frequent in
patients with OA compared with other diseases and to
lead to greater deterioration of physical functions and
QoL. OA increases cardiovascular mortality [26],
worsens the prognosis of arthroplasties, and reduces the
range of possibilities of pharmacological treatment due
to the incompatibility of prescribed drugs to alleviate
joint pain and treat comorbidities [4]. Finally, our results
revealed a high prevalence of gastrointestinal problems
which may be a consequence of the high use of NSAIDs,
the oral OA treatment of choice in the majority of the
cases that are related to gastrointestinal adverse effects
[27].
More than three-quarters of these patients (78%), who
are probably already polymedicated, ask for access to
additional non-drug/non-surgical treatments for their
OA. Non-pharmacological therapies such as physical ac-
tivity or nutritional programs have been recommended
in clinical guidelines and reported to have a positive ef-
fect on the health status and QoL of OA patients [7, 28].
It has been shown that exercise therapy may postpone
total joint replacement [29]. Physical and occupational
therapy-related interventions have proven to reduce pain
in patients with hand OA [30, 31]. Additionally, self-
management programs have shown to improve mental
health and social connectedness, thereby improving
many aspects of OA patients’ lives [32–34].
The high percentage of respondents asking for access
to these interventions is striking considering the exist-
ence of such extended literature describing effective in-
terventions for OA management. This may highlight an
existing gap between the theory on how to improve OA
management and the reality patients have to face when
living with their disease. Health systems should invest
more in implementing health promotion and interven-
tion programs in OA while partnering with patients’ or-
ganizations. Similarly, educational programs should be
promoted, both for health professionals and patients.
Only 58.3% of respondents said their doctors explained
adequately their OA diagnosis and only 53.3% under-
stood their OA treatment options. Educational interven-
tions are extremely important tools able to improve
patients’ ability to self-manage their chronic diseases
hence improving their QoL [35, 36].
Almost all patients reported limitations in physical
and work activities, as well as enormous limitations
in their personal life associated with severe symptom-
atology (i.e., pain, stiffness, loss of flexibility among
others). Pain and other OA-related symptoms can be
reduced by rehabilitation programs focused on allevi-
ating pain and maintaining or improving physical and
psychological function. Rehabilitation is widely recom-
mended as first-line treatment for OA in evidence-
based clinical guidelines [32, 37–39], as they are safer
and, in many cases, more effective at reducing pain
than the best established pharmacological interven-
tions. Also, regular exercise is considered to be a core
treatment for OA and it is universally recommended
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amongst treatment guidelines for all individuals with
OA [40, 41].
When only 26.8% of respondents report being satisfied
with their current treatment plan, it is not surprising
that more than half of the respondents would like to
have access to additional drug treatments, a request
which underlines the urgent need for new medications
for OA. Currently, there is no cure for OA and pharma-
cological treatments can help to relieve symptoms or
delay the progression of the disease. However, many of
these drugs cannot be used for a long time due to their
adverse effects and incompatibility with medications
used for OA- associated comorbidities [26, 42–45]. Fur-
thermore, it has been previously reported that OA pa-
tients are concerned about possible side effects of
medication [46]. This evidence, in association with our
results, highlights the need for investment in research
for new and more active OA pharmacological
treatments.
In this study, only 51.7% of patients reported having a
good QoL; whereas 48.2% were either not satisfied with
their QoL or not sure about their satisfaction with their
QoL. It has to be noted that elderly people can have, in
general, lower expectations in terms of QoL than young
patients [47]. The age range of our study population was
older and this may have been reflected in this survey’s
QoL responses. Additionally, the false conception that
OA is a natural age-related condition may lower the ex-
pectations of QoL of OA patients while highlighting the
need for patient education programs which may have an
impact on OA patients’ perception. When patients were
asked how they would evaluate their QoL if OA was
eliminated, almost 95% of respondents said they would
be more satisfied. This data demonstrates the impact of
OA on the QoL of people affected by this disease and
the urgent need for improvement in OA management
strategies.
Limitations of the study
The results of this pilot study present limitations which
must be acknowledged. The data used in the analyses
were based on patient self-reports, without clinical verifi-
cation of an OA diagnosis, and thus are subject to the
biases that are inherent to this type of data survey. Also,
online questionnaires can be associated with gender and
age-related biases, as women may be more prompt in
using this kind of technology and elderly people may
find it difficult to respond to them.. There is a huge dif-
ference in the number of surveys collected in each of the
participant countries that could reflect cultural percep-
tions of this type of survey and/or technology. Caution
should be taken when interpreting these findings, as
there is a clear predominance of surveys answered by pa-
tients from the USA.
Conclusion
The results of this pilot study represent an important
stepping stone to gain insight into the needs and prior-
ities of OA patients to shape the health care process on
the patient’s view. The results highlight the severe im-
pact of OA on patients’ life due to associated limitations,
symptoms, and comorbidities. Importantly, the vast ma-
jority of patients expressed an interest in gaining access
to non-drug/non-surgical treatment. Health promotion
and self-management strategies addressing unhealthy
weight and low levels of physical activity may improve
the health conditions of patients as well as educational
programs incorporating the patient expert role. Also, pa-
tients are requesting more pharmacological treatments
as an alternative to the symptomatological drugs cur-
rently available on the market which can only alleviate
OA symptoms and may be associated with unwanted ad-
verse effects. This portrait of patients’ perceptions of OA
can provide a baseline to evaluate better quality per-
formance in the future. Starting with these results and
considering the study limitations, the OA Patients Task
Force aims to develop a new international survey that
will enable them to reach a larger population and collect
more data on the patients’ population characteristics (i.e.
socioeconomic), perception and patient needs which can
allow to the performance of population distribution ana-
lyses and the ability to understand the specific needs and
characteristics of different demographic and social
groups. Depth analysis of the reasons behind the pa-
tients’ needs may contribute to the design of personal-
ized strategies for OA management and treatment.
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